Merck 2Q13 2Q Revenues: $11.0 billion (-11%) 2Q Earnings: $906 million (-50%) YTD Revenues: $21.7 billion (-10%) YTD Earnings: $2.5 billion (-29%) Comments: An 80% drop in Singulair sales led to a $1.1 billion shortfall in revenues for Merck in 2Q13, wiping out scant gains for top products Januvia (+1% to $1.1 billion), Zetia (+3% to $650 million), Remicade (+2% to $527 million) and Janumet (+16% to $474 million). A stronger dollar also hurt Januvia revenues, which would have posted 7% grow...